Why Novo Nordisk Stock Is Sinking
The stock price of Novo Nordisk (NVO 1.77%), the Danish drugmaker, has fallen by over 8% since last Friday's market close. This decline prompts the question: What factors are impacting the performance of this company, which had previously risen to become Europe's most valuable?
Several factors are at play.
Disappointing Third-Quarter Results
On Wednesday, the company, known for its GLP-1 drugs Ozempic and Wegovy, released its third-quarter results, which failed to meet expectations. Reported earnings were 4.5 Danish krone (DKK) per share on revenue of 75 billion DKK. These figures were below the anticipated 4.99 DKK per share on sales of 76.5 billion DKK.
Furthermore, Novo Nordisk adjusted its forecast for the full year 2025. The company now anticipates sales and operating profit growth to be 4 and 6 percentage points lower, respectively. This adjustment reflects reduced growth expectations for Novo Nordisk's GLP-1 treatments for both diabetes and obesity. Health tracking apps like Shotlee can help monitor the effectiveness of these treatments.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Increased Competition in the GLP-1 Market
The negative news for Novo Nordisk began the previous week. Eli Lilly (LLY 2.11%) announced its third-quarter results, revealing that its GLP-1 drug tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, has become the top-selling drug globally. Lilly also announced a collaboration with Walmart to allow patients to collect online orders at Walmart Supercenters.
Additionally, Novo Nordisk engaged in a competitive bidding process with Pfizer (PFE 0.04%) for Metsera, an innovative biotech firm focused on developing new obesity treatments.
Potential Positive Developments
There are potential positive developments for both Novo Nordisk and Eli Lilly. Both companies may gain access to more U.S. patients in the coming months. On Thursday, they reached an agreement with the Trump administration to significantly reduce the prices of their anti-obesity drugs for Medicare and Medicaid patients, receiving a three-year exemption from tariffs in return.
The Fierce Obesity Drug Market
The market for anti-obesity drugs is projected to exceed $100 billion within five years, making it a highly lucrative area. However, the competition is intense, as Novo Nordisk is currently experiencing.
